OpGen (NASDAQ:OPGN) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com began coverage on shares of OpGen (NASDAQ:OPGN) in a research report issued to clients and investors on Tuesday. The brokerage set a “sell” rating on the medical research company’s stock.

OpGen Stock Performance

Shares of OPGN stock opened at $2.70 on Tuesday. The business has a fifty day simple moving average of $1.29 and a 200 day simple moving average of $1.44. OpGen has a twelve month low of $0.53 and a twelve month high of $9.90.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.